CEO Dr. Ron Najafi to Provide Webcast Corporate Presentation EMERYVILLE, Calif., Feb. 8, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective Aganocide ® compounds for the topical treatment and prevention of antibiotic-resistant infections, will present at the 13 th Annual BIO CEO & Investor Conference being held at the Waldorf Hotel in New York City. Dr. Ron Najafi, NovaBay's Chief Executive Officer, will address attendees on Tuesday, February 15, 2011 at 8:00 AM Eastern Time (5:00 AM Pacific Time). Those interested in listening to Dr. Najafi's presentation can use the following link to access the webcast: http://www.veracast.com/webcasts/bio/ceoinvestor2011/19201323.cfm . The replay will be available one hour after the event and will expire on May 15, 2011. More information about the BIO CEO & Investor Conference is available at: http://www.bio.org/bioceo/About-BIO-CEO/ . To arrange a meeting with NovaBay management, please contact Adam Holdsworth at 212-825-3210, or e-mail firstname.lastname@example.org. About NovaBay's Aganocide Compounds NovaBay's Aganocide compounds are novel, synthetic N-chlorinated antimicrobial molecules specifically designed and developed to mimic the body's natural defense against infection. These topical compounds maintain biological activities while demonstrating improved stability over the naturally occurring N-chlorinated antimicrobial molecules. In preclinical testing, Aganocide compounds have been shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi. NovaBay's Aganocide compounds have the potential to deliver the same or better efficacy than topical antibiotics, and to address the growing problem of antibiotic resistance by employing a novel mechanism of action. About NovaBay Pharmaceuticals, Inc. NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's Aganocide compounds are being developed for the topical treatment and prevention of a wide range of infections without causing bacterial resistance. The company is developing commercial opportunities in four distinct healthcare markets: dermatology, ophthalmology, urology and hospital infections. Each of these market segments contains indications that are poorly served or have no approved FDA treatments available, with multiple hundred-million to billion-dollar revenue opportunities. NovaBay's strategy is to address these markets either through partnerships and collaborations, or by building an internal organization to strategically market products when appropriate from a commercial standpoint. NovaBay has internal development programs aimed at addressing hospital infections, chronic non-healing wounds, urinary catheter blockage and encrustation (UCBE), and onychomycosis. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections, as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in impetigo, acne and other dermatological indications. For more information on NovaBay, visit: www.NovaBaypharma.com .
CONTACT: NovaBay Pharmaceuticals, Inc. Thomas J. Paulson, Chief Financial Officer 510-899-8800 tjpaulson@NovaBaypharma.com The Investor Relations Group Investor Relations: Adam Holdsworth 212-825-3210 email@example.com Public Relations: Laura Colontrelle 212-825-3210 firstname.lastname@example.org